Indaptus Therapeutics Q1 EPS $(0.23) Beats $(1.87) Estimate
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Entered Into $6M Securities Purchase Agreement With Investor David Lazar
What Does the Market Think About Indaptus Therapeutics Inc?
Market-Moving News for December 24th
Indaptus Therapeutics Appoints David Lazar As The Co-Chief Executive Officer
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Indaptus Therapeutics Q3 EPS $(2.98) Beats $(4.17) Estimate
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 109.76%
Indaptus Therapeutics Shares Resume Trade
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 77.13%
Indaptus Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 50.91%
Indaptus Therapeutics shares are trading lower. The company announced recent updates for its ongoing INDP-D101 clinical trial.
Indaptus Therapeutics Provides Clinical Update
Indaptus Reports Partial Response From Decoy20 Monotherapy In Urothelial Cancer; Combo With PD-1 Inhibitor Shows Favorable Safety
Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference
Indaptus Therapeutics: Files For Mixed Shelf Offering Of Up To $200M
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.